| 前收市價 | 28.86 |
| 開市 | 28.86 |
| 買盤 | 28.65 x 1400 |
| 賣出價 | 28.59 x 3200 |
| 今日波幅 | 28.50 - 28.98 |
| 52 週波幅 | 25.20 - 31.54 |
| 成交量 | |
| 平均成交量 | 30,564,940 |
| 市值 | 163.541十億 |
| Beta 值 (5 年，每月) | 0.62 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.46 |
| 業績公佈日 | 2024年10月29日 |
| 遠期股息及收益率 | 1.68 (5.82%) |
| 除息日 | 2024年11月08日 |
| 1 年預測目標價 | 33.11 |
BenzingaJust After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for lower respiratory tract disease (LRTD). The data show that the vaccine has the potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV. In the U.S. alone, the number of adults aged 18-49 with at least one risk factor that could put them at risk for RSV disease could exceed 21 mill
ZacksWill New Drugs Help Biogen Surpass Q3 Earnings Estimates?
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
BenzingaCDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted for expanded usage recommendation for Merck & Co Inc’s (NYSE:MRK) and Pfizer Inc’s (NYSE:PFE) pneumococcal conjugate vaccines. The CDC panel has recommended lowering the pneumococcal vaccination age from 65 to 50 years old. “ACIP’s vote to expand adult pneumococcal vaccination to now include all adults aged 50 and older marks an important milestone in Pfizer’s long-
